Despite the evidence demonstrating the favorable effects of SGLT2-i on the main complications of T2DM underlying the development of diabetic foot, no prospective longitudinal study has evaluated the reduction in the risk of developing DF in patients treated with SGLT2-i compared to other treatments. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.